Johnson & Johnson’s innovative Medicine segment crossed $60bn in full-year 2025 revenue for the first time, driven by Oncology and Neuroscience.
CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
SPRAVATO in Neuroscience delivered 57.4% full-year growth, reaching $1.7bn, while newly acquired CAPLYTA contributed $700mn from the April 2025 Intra-Cellular Therapies acquisition, with management reiterating a greater than $5bn peak-year sales target for CAPLYTA.
Johnson & Johnson stock price surged to $248.43 as of Feb 27, 2026, from $163.77 as of Feb 27, 2025. The stock reached a 52-week high of $248.94 and its 52-week low was $141.50
Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
https://www.crispidea.com/report/johnson-johnson-jnj-equity-report-q3fy25/
$264.00
Mondelez International (Q2FY26)- Emerging Markets remained the company's strongest growth engine in Q2FY26, with organic revenue increasing 4.4%, supported by strong volume and mix performance across most snacking categories.
$240.00
Hewlett Packard Enterprise delivered one of its strongest quarters as enterprise demand accelerated across networking, Cloud & AI, storage, and hybrid cloud.
$224.00
Okta Inc Q1FY27 - Okta continues to strengthen its position within large enterprise customers, which remains the primary driver of recurring revenue growth.
$240.00
UiPath is successfully evolving from a traditional RPA provider into an enterprise AI and process orchestration platform.
$240.00
This sector report provides a forward-looking assessment of the quantum cybersecurity landscape, analyzing how the rapid advancement of quantum computing is necessitating a fundamental shift toward quantum-resistant infrastructure.
$1,100.00
As we approach 2026, the APAC region continues to stand out as a global growth engine. But for the institutional investor, the real “investment season” is happening right now.
$350.00
Semiconductors remain vital to modern electronics, powering devices like smartphones, tablets, and PCs. While the industry has recovered from pandemic disruptions, it now faces geopolitical tensions, regulatory shifts, and supply chain diversification efforts.
$1,450.00
Tokenization is reshaping how financial assets are issued, settled, and stored. The technology is proven, regulations are advancing, and major asset managers are already moving capital onto blockchain-based systems.
$230.00
You may check out all the available products and buy some in the shop.
Continue Shopping